Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy
Cancers · 17.02.2026 · 18 (4) · 647
DOI: 10.3390/cancers18040647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.02.2026. Verfasst von Silvia Filippi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular Genetics of Aging, Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research (MUR), Italian Ministry of University and Research.
Abstract (Originalsprache)
Background/Objectives: Melanoma is the deadliest form of skin cancer. Resistance to alkylating agents such as Temozolomide (TMZ) and Dacarbazine (DTIC) limits their clinical benefit, as these drugs remain palliative options when immunotherapies and targeted treatments fail. CSA/ERCC8 is a key component of transcription-coupled nucleotide excision repair (TC-NER), a pathway responsible for removing UV-induced DNA lesions. In principle, loss of a DNA repair factor would be expected to increase carcinogenesis. However, although CSA loss-of-function causes Cockayne Syndrome (CS), affected patients do not exhibit increased skin cancer incidence, suggesting that CSA impairment promotes apoptosis rather than tumor development. This paradox raises the possibility that CSA inhibition may selectively target melanoma cell survival pathways.
Methods
The expression of CSA/ERCC8 was analyzed by qRT-PCR and Western blot. ERCC8 was silenced using antisense oligonucleotides. Cell viability, apoptosis, cell cycle progression, drug sensitivity, and DNA damage were assessed by functional assays, including IC50 determination and Bliss analysis for drug interactions.
Results
We identified CSA/ERCC8 as a driver of melanoma chemoresistance. CSA was markedly overexpressed in primary and metastatic melanoma cells. ERCC8 silencing reduced proliferation, induced apoptosis, and significantly enhanced sensitivity to low doses of TMZ and DTIC while sparing normal cells.
Conclusions
CSA represents a promising therapeutic target to overcome chemoresistance in melanoma. Its inhibition enhances the efficacy and selectivity of alkylating agents, supporting its potential as a salvage strategy for refractory disease and warranting further preclinical and clinical investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Molecular Genetics of Aging, Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy.
ORCID-Profile: Silvia Filippi, Emma Valeri, Valeria Bartolocci, Elena Paccosi, Diletta Guzzon, Luca Proietti-De-Santis
Förderung
- Ministry of University and Research (MUR)
- Italian Ministry of University and Research
Zitieren
APA
Filippi, S., Valeri, E., Bartolocci, V., Paccosi, E., Guzzon, D., & Proietti-De-Santis, L. (2026). Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy. Cancers, 18(4), 647. https://doi.org/10.3390/cancers18040647
Vancouver
Filippi S, Valeri E, Bartolocci V, Paccosi E, Guzzon D, Proietti-De-Santis L. Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy. Cancers. 2026;18(4):647. doi:10.3390/cancers18040647
BibTeX
@article{Filippi2026,
author = {Filippi, Silvia and Valeri, Emma and Bartolocci, Valeria and Paccosi, Elena and Guzzon, Diletta and Proietti-De-Santis, Luca},
title = {Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy},
journal = {Cancers},
year = {2026},
volume = {18},
number = {4},
pages = {647},
doi = {10.3390/cancers18040647}
}
EUVIMED